Systemic therapy for bladder cancer is costly and should be weighed against the clinical outcomes likely to be achieved.
health care costs
In patients with HER2-positive metastatic gastric cancer, subcutaneous administration of a common therapy results in significant time savings for health care providers as well as reduced costs.
A 21-gene assay poses an overall incremental cost increase to the health care system in the short-term, despite lower rates of chemotherapy use.
Patients treated with dasatinib for newly diagnosed chronic myeloid leukemia experienced greater health care resource utilization and associated costs due to infection than patients treated with nilotinib.
A recent cost-effectiveness analysis compared novel agents and chemotherapy for older Medicare patients with multiple myeloma.
Patients receiving treatment for ovarian cancer experienced a significant out-of-pocket financial burden, due largely to cost disparities across treatment types and a lack of definitive treatment options.
Next-generation sequencing may be economically beneficial for select patients with treated in the community oncology setting, but it should be carefully applied due to potential associated financial burdens.
The future of clinical pathways largely depends on alternative payment models such as the Oncology Care Model sponsored by CMS, according to Edward Stepanski, PhD.
The treatment of advanced melanoma represents a significant burden to the health system, and differs by insurance type and geographic location, according to the results of a regional analysis.